

# UNITED STATES EPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

B
---

FIRST NAMED INVENTOR					ATTORNEY DOCKET NO.	
APPLICATION NO.	FILING DATE		FIRST NAMED INV			
09/601,645	08/04/00	DAHM			M	24741-1509US
		· -		$\neg$		EXAMINER
HM12/0501				1	ZITOMER,S	
STEPHANIE SEIDMAN					ART UNI	T PAPER NUMBER
HELLER EHRMAN WHITE & MCAULIFFE 7TH FLOOR 4250 EXECUTIVE SQUARE				1655	=D:	
LA JOLLA CA	3			DATE MAIL	05/01/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Office Action Summary

Application No.

Examiner

Applicant(s)

09/601,645

Art Unit

1655



Office Action Cummer,	Stephanie Zitomer	1655
The MAILING DATE of this communication appear	rs on the cover sheet with the corres	pondence address
		g .
Period for Reply  A SHORTENED STATUTORY PERIOD FOR REPLY IS SET THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communication of the period for reply specified above is less than thirty (30) data be considered timely.  - If NO period for reply is specified above, the maximum statuto communication.  - Failure to reply within the set or extended period for reply will.  - Any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b).	CFR 1.136 (a). In no event, however, nication.  ays, a reply within the statutory minimu  ry period will apply and will expire SIX (  , by statute, cause the application to be the mailing date of this communication	may a reply be timely mod  m of thirty (30) days will  (6) MONTHS from the mailing date of this  come ABANDONED (35 U.S.C. § 133).  , even if timely filed, may reduce any
Status  1) Responsive to communication(s) filed on		
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This  3) ☐ Since this application is in condition for allowan closed in accordance with the practice under Experimental Experiments.	action is non-final.	secution as to the merits is
Disposition of Claims	·	are pending in the application.
4) 💢 Claim(s) <u>1-68</u>		
4) 💢 Claim(s) <u>1-68</u> 4a) Of the above, claim(s)	10.	is/are allowed.
		<del></del>
7) ☐ Claim(s)	uio dazjeri	
Application Papers  9) The specification is objected to by the Examin  10) The drawing(s) filed on  11) The proposed drawing correction filed on  12) The oath or declaration is objected to by the	is/are objected to by the Examina-	r. ved b}□ disapproved.
Priority under 35 U.S.C. § 119  13) Acknowledgement is made of a claim for for a) All b) Some* c) None of:  1. Certified copies of the priority documer  2. Certified copies of the priority documer  3. Copies of the certified copies of the priority application from the Internation  *See the attached detailed Office action for a list  14) Acknowledgement is made of a claim for document is made of a claim for docu	nts have been received.  Ints have been received in Applicat  Iority documents have been receiv  I Bureau (PCT Rule 17.2(a)).  I of the certified copies not receiv	ed in this National Stage
Attachment(s)	18) Interview Summary (PTO-41)	3) Paper No(s)
15) X Notice of References Cited (PTO-892)  16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Ap	plication (PTO-152)
16) Notice of Dranspelson's Attended 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	20) Other:	

Application/Control Number: 09/601,645

Art Unit: 1655

#### RESTRICTION

#### **Application status**

1. The present application is a 371 filing, the national stage of PCT/EP99/00716 filed February 3, 1999.

applicant is advised that when the application is taken up for examination the filing date of the German priority document, 198 04 372.4 filed February 4, 1998, will not be considered because the document has not been translated into English.

2. Prior art has been found in the application but is not accompanied by an Information Disclosure Statement or a 1449 form. Applicant is advised that those references that are not in English will not be considered.

### Restriction: Lack of unity of invention

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-38 and 52-67, drawn to a nucleic acid amplification method; Group II, claim(s) 39-51 and 68, drawn to an oligonucleotide and oligonucleotide kit.

4. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature, mRNA encoding the catalytic subunit of human telomerase, was known in the art and the cDNA sequence was available from GenBank as disclosed by Nakamura et al. (15 August 1997) (SCIENCE 277: 955-959). The claimed method of concentrating and quantifying tumor cells in body fluid by measuring the amount of specific mRNA in the cells was practiced in the art as taught by Sidransky (5,726,019) (see examples).

#### Closing

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephanie Zitomer whose telephone number is (703) 308-

Application/Control Number: 09/601,645

Art Unit: 1655

3985. The examiner can normally be reached on Monday through Friday from 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152. The official fax phone number for this Group is (703) 308-4242. The unofficial fax number is (703) 308-8724.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Stephanie Zitomer, Ph.D

April 27, 2001

Herman Car